Coronavirus Updates: India logs 43,733 new COVID-19 cases, 930 fatalities

The active cases have further declined to, 4,59,920 and comprise 1.50 per cent of the total infections, while the national COVID-19 recovery rate has improved to 97.18 per cent, the data updated at 8 am showed.

Moneycontrol News
July 07, 2021 / 10:17 AM IST

Sanofi has partnered with British pharmaceutical giant GlaxoSmithKline (GSK) to develop an adjuvanted recombinant-protein COVID-19 vaccine candidate.

India added 43,733 new cases of coronavirus taking the total tally to 3,06,63,665, while the active cases further declined to 4,59,920, according to the Union Health Ministry data updated on Wednesday.

The death toll climbed to 4,04,211 with 930 daily fatalities.

The active cases have further declined to, 4,59,920 and  comprise 1.50 per cent of the total infections, while the national COVID-19 recovery rate has improved to 97.18 per cent, the data updated at 8 am showed.

Also, 19,07,216 tests were conducted on Tuesday taking the total cumulative tests conducted so far for detection of COVID-19 in the country to 42,33,32,097.

The daily positivity rate  was recorded at 2.29 per cent . It has been less than three per cent for 16 consecutive days, the ministry said, adding the weekly positivity rate has declined to  2.39 per cent.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Recoveries continue to outnumber daily new cases for the 55th consecutive day.The number of people who have recuperated from the disease surged to 2,97,99,534,  while the case fatality rate  stands at 1.32 per cent, the data stated

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh  on August 23, 40 lakh on September 5 and 50 lakh on September 16.It went past  60 lakh on September 28,  70 lakh on  October 11, crossed 80 lakh on October 29,  90 lakh on November 20 and surpassed the one-crore mark on December 19.India crossed the grim milestone of two crore on May 4 and three crore on June 23.

(With PTI inputs)
Moneycontrol News
Tags: #coronavirus #Covid-19 #Current Affairs #India #vaccine
first published: Jul 7, 2021 10:17 am